Saliva Test for Cancer
Color Genomics Raises $45M in Series B. With a little Help from Bono
28 SEP 2016 – Liz Harley [Original Article]
Yep, you read that correctly. Maybe the U2 front man has finally found what he’s looking for (sorry) by investing in cancer testing startup Color Genomics. The company has announced a series B investment round of $45M, led by General Catalyst with participation from the famous Irish wearer of large sunglasses. Existing investors Susan L. Wagner, 8VC, Khosla Ventures and Emerson Collective also provided additional cash.
Color Genomics offer a $249 saliva test kit that detects high-risk cancer mutations linked to eight different cancer sub-types, including breast, colorectal, ovarian and prostate.
“We’re in the middle of one of the greatest shifts seen in health. Increased access to genetic information is enabling doctors and their patients to create personalized plans for better prevention, detection and treatment of hereditary disease,” said Elad Gil, CEO and co-founder of Color Genomics. “The new funding will go toward bringing even more people access to potentially life-saving genetic information and building the open databases necessary to further global research and development around major diseases.”
Color have raised $60 million since its launch in 2015.